SLC26A2 and posterior cortical atrophy: They also expressed tumour suppressors (e.g., SULF1, EBF3) [89,90], many protocadherin family members, which have both suppressor and oncogenic roles in PCa [91], and solute carrier family members (e.g., SLC35F1, SLC26A2) implicated in drug uptake and efficacy modulation [92].